Amaranth Medical Inc.
This article was originally published in Start Up
Executive Summary
With technology developed at Nanyang Technological University. Amaranth has entered into an increasingly competitive race involving start-ups with their eyes on a considerable prize-the creation of a vascular stent composed of biodegradable polymers.
You may also be interested in...
ACC Wrap-Up: Device Companies Win a Few, Lose a Few
Several interesting studies came out of this year's joint meeting of the American College of Cardiology and Society for Cardiovascular Angiography and Interventions. These studies--many of them about drug-eluting stents--will impact device manufacturers in both positive and negative ways.
Arterial Remodeling Technologies
Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.
Bioabsorbable Therapeutics Inc.
Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.